The board of directors of the Suzhou Basecare Medical Corporation Limited announced that the resolution regarding the appointment of Mr. Lam as an independent non-executive Director was approved at the 2023 first extraordinary general meeting of the Company (the "EGM") held on July 13, 2023. The appointment of Mr. Lam as an independent non-executive Director has become effective on the date of the EGM, being July 13, 2023. Poll results of the EGM are set out in the poll results announcement of the Company dated July 13, 2023. The Company has entered into a letter of appointment with Mr. Lam in relation to his appointment as an independent non-executive Director for a term commencing from the date of approval of his appointment at the EGM, being July 13, 2023, and expiring on the conclusion of the first session of the Board of Directors. This term of office is terminable by either party serving on the other not less than three months' written notice, and subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"). Under the terms of the letter of appointment, Mr. Lam will be entitled to an annual director fee of HKD 200,000 (before tax). The remuneration of Mr. Lam is determined with reference to his duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee from time to time. Mr. Lam has not entered into nor proposed to enter into any service contracts, which fall within the meanings of Rule 13.68 of the Listing Rules requiring the prior approval of shareholders of the Company at general meetings, with the Company. The Board announced that, following the resolution regarding the appointment of Mr. Lam as an independent non-executive Director being passed at the EGM, with effect from July 13, 2023, Mr. Lam has been appointed as the chairman of the Audit Committee and a member of each of the Nomination Committee and the Remuneration and Appraisal
Committee. Following the above appointments, the composition of the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee are as follows: (1) the Audit Committee comprises two independent non-executive Directors, namely Mr. Lam (chairman of the Audit Committee) and Dr. KANG Xixiong, and one non-executive Director, namely Mr. WANG Weipeng; (2) the Nomination Committee comprises two independent non-executive Directors, namely Dr. KANG Xixiong and Mr. Lam, and one executive Director, namely Dr. LIANG Bo (chairman of the Nomination Committee); and
(3) the Remuneration and Appraisal Committee comprises two independent non-executive Directors, namely Dr. KANG Xixiong (chairman of the Remuneration and Appraisal Committee) and Mr. Lam, and one executive Director, namely Dr. LIANG Bo.